Archive for the ‘Gene Therapy Research’ Category

DUBLIN, May 19, 2020 /PRNewswire/ -- The "Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) [based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches] features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity.

The report also features the likely distribution of the current and forecasted opportunity across:

Market Summary and Insights

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer's disease, brain cancer, multiple sclerosis. Parkinson's disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer's disease.

Similarly, Parkinson's disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. Further, experts believe that there is a critical relationship between recent pandemic of novel Coronavirus (COVID-19) and the cardiovascular and cerebrovascular systems. People suffering from certain CNS complications are at a relatively higher risk of COVID-19 infection due to a compromised immune system.

It is estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB.

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies.

The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI's PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

In addition to other elements, the study includes:

In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Questions Answered

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/wgim84

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/blood-brain-barrier-markets-insights-and-forecast-to-2030-by-type-of-molecule-target-disease-indications-key-contributing-technologies-leading-drug-developers-and-key-geographical-regions-301061789.html

SOURCE Research and Markets

Link:
Blood-Brain Barrier Markets Insights and Forecast to 2030 by Type of Molecule, Target Disease Indications, Key Contributing Technologies, Leading Drug...

Facts & Factors Market Research added a recent report on Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026 to its research database. The Cancer Gene Therapy Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global industry.

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Cancer Gene Therapy industry. The report analyzes and declares the historical and current trends analysis of the Cancer Gene Therapy industry and subsequently recommends the projected trends anticipated to be observed in the Cancer Gene Therapy market during the upcoming years.

The Cancer Gene Therapy market report analyzes and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire Cancer Gene Therapymarket. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value from FY 2016 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer Gene Therapy industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Request an Exclusive Free Sample Report of Cancer Gene Therapy Market: https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Our Every Free Sample Includes:

A research report overview, TOC, list of tables and figures, an overview of major market players and key regions included.

Some of Top Market Players Analysis Included in this Report:

Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics

The Market Player Analysis based on some of below Factors:

Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/cancer-gene-therapy-market-by-type-ex-vivo-898

This research report provides forecasts in terms of CAGR, and Y-O-Y growth. This helps to understand the overall market and to recognize the growth opportunities in the global Cancer Gene Therapy Market. The report also includes a detailed profile and information of all the major market players currently active in the global Cancer Gene Therapy Market. The companies covered in the report can be evaluated based on their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies to stay competitive in the market.

The global Cancer Gene Therapy Market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period. The related data and statistics collected from the regulatory organizations are portrayed in the Cancer Gene Therapy Market report to assess the growth of each segment.

The global Cancer Gene Therapy Market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period. The related data and statistics collected from the regulatory organizations are portrayed in the Cancer Gene Therapy Market report to assess the growth of each segment.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization).

Available Customization Options:

The Cancer Gene Therapy Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

KEY REPORT POINTERS & HIGHLIGHTS:

To Know More about Discount on Specific Report, Kindly Mail us at [[emailprotected]]with Your requirement. We will send you a quote and discount offer, if available.

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +8621 80360450

E-Mail: [emailprotected]

Web:https://www.fnfresearch.com

Excerpt from:
The Impact of Coronavirus on The Cancer Gene Therapy Market 2020 Projected to Witness Robust Development by 2026 3w Market News Reports - 3rd Watch...

A new study on the Gene Therapy market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market during the historical period 2015 2019. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 2026. The insights and analytics on the Gene Therapy market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment.Despite the ongoing issues, the worldwide revenue of gene therapy market will surpass US$ 5 Bn by 2026, exhibiting a stellar growth rate.

Key stakeholders in the Gene Therapy market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Many in recent months have overhauled their strategies to remain agile in the backdrop of worldwide disruptions caused by the COVID-19 pandemic.

Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The study also offers scrutiny of the changing government policies amid COVID-19 disruptions. Policymakers in developing and developed nations are framing new regulations to meet the continuing macrocosmic shocks by COVID-19 pandemic. The authors of the report have taken into account the impact analysis of the pandemic, and have elaborated on the trends that will be crucial to the upcoming competitive landscape. New entrants, as well as established players who want to emerge as leaders in the post-COVID era, are taking the impact analysis seriously.

The following insights and evaluations are worth knowing for any market participant, helping them in ascertaining the prevailing dynamics and the future trajectories of the Gene Therapy market. They are a part of the estimations of the opportunities in various segments.

Some of the insights and market estimations that make this study unique in approach and effective in guiding stakeholders in understanding the growth dynamics. The study provides:

The regional segmentation of the Gene Therapy market is done as follows:

On the basis of product types, the Gene Therapy market report offers insight into major adoption trends for the following segments:

Key end-users covered in the study include:

Companies profiled in the report are:

To Know More Information about This Report, Ask The Analyst @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

How can Fact.MR Make Difference?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release- https://www.factmr.com/media-release/1409/global-gene-therapy-market

Read this article:
Gene Therapy Market Revenue Status & Forecast Report 2020 to 2026 - The Cloud Tribune

Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer

LA JOLLA, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy (ISCT) and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer.

I was delighted to be invited to review the exciting array of clinical trials of innate immunotherapies for the specialized translational scientists who read SCTM. The innate immune response is so often overlooked as a therapeutic tool, but its conserved presence throughout evolution suggests that it is the most important mediator of tumor immune surveillance, said Prof Lowdell.

This publication is one of the first to comprehensively review clinical trials of the common innate immune effector cells. It highlights the breadth of innate immunotherapy options and the global interest in harnessing this side of the immune system. Prof. Lowdell has been a leader in identifying how cancer evades innate immune surveillance by NK cells and how to overcome those resistance mechanisms to allow NK cells to attack the tumor.

Of all the innate immune effectors in trial, NK cells have been, and remain, at the forefront. More is understood about the NK:tumour cell interaction than any of the other cells and many of the mechanisms which impair function are understood. Uniquely among the innate immune effector cells, NK cells have been shown to be effective without ex vivo manipulation but with in vivo activation with monoclonal antibodies such as Rituximab and Herceptin and with cytokines such as IL-2 and, more recently, IL-15 derivatives, said Prof Lowdell. In this vein, INmune Bio has developed INKmune, an off-the-shelf therapy to activate a cancer patients NK cells in vivo to attack their own cancer cells. INKmune is scheduled to enter clinical trials in the next 12 months in the treatment of patients with ovarian cancer and high-risk MDS. To learn more about INKmune, please visit our website at http://www.inmunebio.com.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visitwww.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, XPro1595, LIVNate, DN-TNF and INKmune are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:David Moss, CFO (858) 964-3720DMoss@INmuneBio.com

Investor Contact:James Carbonara (646) 755-7412James@haydenir.com

Read more from the original source:
Killers at the Crossroad A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio,...

North America, Europe, China, Japan, Rest of the World,May 2020, The Viral Vector & Plasmid DNA Manufacturing Market research report includes an in-sight study of the keyViral Vector & Plasmid DNA Manufacturing Market Researchprominent players along with the company profiles and planning adopted by them. This helps the buyer of the Viral Vector & Plasmid DNA Manufacturing report to gain a clear view of the competitive landscape and accordingly plan Viral Vector & Plasmid DNA Manufacturing market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Viral Vector & Plasmid DNA Manufacturing specifications, and company profiles. The Viral Vector & Plasmid DNA Manufacturing study is segmented by Module Type, Test Type, And Region.

The market size section gives the Viral Vector & Plasmid DNA Manufacturing market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Viral Vector & Plasmid DNA Manufacturing industry over a defined period.

Download Full PDF Sample Copy of Report:jcmarketresearch.com/report-details/11639/sample

The research covers the current market size of the Viral Vector & Plasmid DNA Manufacturing Market Researchand its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Viral Vector & Plasmid DNA Manufacturing Market Research, by applications Biopharmaceutical Companies Research Institutes Main Ain overall market. The in-depth information by segments of Viral Vector & Plasmid DNA Manufacturing market helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the Viral Vector & Plasmid DNA Manufacturing Market Research.

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of Viral Vector & Plasmid DNA Manufacturing Market Research. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Global Viral Vector & Plasmid DNA Manufacturing (Thousands Units) and Revenue (Million USD) Market Split by Product Type such as Adenovirus Retrovirus Plasmid DNA Others M

The research study is segmented by Application such as Laboratory, Industrial Use, Public Services & Others with historical and projected market share and compounded annual growth rate.Global Viral Vector & Plasmid DNA Manufacturing (Thousands Units) by Regions (2019-2025)

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Viral Vector & Plasmid DNA Manufacturing in these regions, from 2012 to 2022 (forecast), covering

Get Exclusive Discount:jcmarketresearch.com/report-details/11639/discount

There are 15 Chapters to display theViral Vector & Plasmid DNA Manufacturing Market Research.

Chapter 1, to describe Definition, Specifications and Classification of Viral Vector & Plasmid DNA Manufacturing , Applications of Viral Vector & Plasmid DNA Manufacturing , Market Segment by Regions;

Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis ofViral Vector & Plasmid DNA Manufacturing, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis by Merck uniQure The Cell and Gene Therapy Catapult Waisman Biomanufacturing Addgene Creative Biogene Novasep Cobra Biologics Aldevron;

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc.,Viral Vector & Plasmid DNA ManufacturingSegment Market Analysis Adenovirus Retrovirus Plasmid DNA Others M;

Chapter 7 and 8, to analyze theViral Vector & Plasmid DNA ManufacturingSegment Market Analysis (by Application) Major Manufacturers Analysis ofViral Vector & Plasmid DNA Manufacturing;Merck uniQure The Cell and Gene Therapy Catapult Waisman Biomanufacturing Addgene Creative Biogene Novasep Cobra Biologics Aldevron

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Adenovirus Retrovirus Plasmid DNA Others M, Market Trend by Application Biopharmaceutical Companies Research Institutes Main A;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyze the Consumers Analysis ofViral Vector & Plasmid DNA Manufacturing;

Chapter 12, to describeViral Vector & Plasmid DNA ManufacturingResearch Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describeViral Vector & Plasmid DNA Manufacturingsales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquiry before Buying The full report @:jcmarketresearch.com/report-details/11639/enquiry

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:JCMARKETRESEARCHJay (Marketing Manager)Phone:+1 (925) 478-7203Email:[emailprotected]

More:
Viral Vector & Plasmid DNA Manufacturing Market Rising Growth With Keyplayer: Merck uniQure The Cell and Gene Therapy Catapult Waisman...

Global Viral Clearance Market is expected to rise from its initial estimated value of USD 517million in 2016 to an estimated value of USD 2457 million by 2026, registering a CAGR of 21.50% in the forecast period of 2016-2026. Increasing investment on R&D is driving the growth of this market.Some of the major players operating in global viral clearance market areInternational, Inc., Lonza, Sigma-Aldrich Co., Wuxi Pharmatech (Cayman) Inc., Merck & Co., Thermo Fisher Scientific Inc., Texcell, BSL Bioservice, Avance Biosciences, SGS SA, Eurofins Scientific, General Electric, Danaher, Sartorius AG, Agilent Technologies, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Hospitech, CSL Behring, Illumina, Inc., Eppendorf AG, PromoCell GmbH, HiMedia Laboratories, BD, Biospherix, Ltd, , and Novogene Corporation among others

Get Sample Report + All Related Graphs & Charts @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-viral-clearance-market

Competitive Analysis:

Global viral clearance market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of viral clearance market for Global, Europe, North America, Asia Pacific, South America, Middle East & Africa.

Global Viral Clearance Market By Method (Viral Detection Method, Viral Removal, Viral Inactivation), Application (Vaccines and Therapeutics, Blood and Blood Products, Cellular and Gene Therapy Products, Tissue and Tissue Products, Stem Cell Products), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Market Definition:

Viral clearance is stated as the removal of contaminated viral by chromatography technique. The development process for monoclonal antibodies, blood derived product , glycoprotein and recombinant protein. To ensure that therapeutic drugs derived from certain sources are fully rid of any viral contamination, these protein solutions undergo viral clearance to inactivate or remove viral materials.

Market Drivers

Market Restraints

Grab Your Report at an Impressive Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-viral-clearance-market

Segementation: Global Viral Clearance Market

By Method

By Application

By End User

By Geography

Key Developments in the Market:

Reasons to Purchase this Report

Key Insights in the report:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Global Viral Clearance Market is Thriving with Rising Latest Trends by 2027 | Top Players- International, Inc., Lonza, Sigma-Aldrich Co., Wuxi...

Detailed Study on the Global Gene Therapy Market

A recent market study throws light on some of the leading factors that are likely to influence the growth of the Gene Therapy market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current Gene Therapy market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.

As per the report, the Gene Therapy market is forecasted to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key dynamics of the Gene Therapy market including the drivers, restraints, opportunities, and trends are thoroughly analyzed in the presented report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2653033&source=atm

The Research Aims to Addresses the Following Doubts Pertaining to the Gene Therapy Market

The report on the Gene Therapy market provides a birds eye view of the current proceeding within the Gene Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Gene Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Gene Therapy market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2653033&source=atm

Gene Therapy Market Segmentation

Competitive Landscape

The competitive landscape section of the report elaborates on the recent developments and innovations introduced by prominent players in the Gene Therapy market. The growth potential, revenue growth, product range, and pricing strategies of each market player in inspected in the report with precision.

End-use Industry Assessment

The report segments the Gene Therapy market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the Gene Therapy in each end-use industry.

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Gene Therapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy market.The following players are covered in this report:Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.AdvantageneGene Therapy Breakdown Data by TypeEx vivoIn VivoGene Therapy Breakdown Data by ApplicationCancerMonogenicInfectious diseaseCardiovascular diseaseOther

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2653033&licType=S&source=atm

Essential Findings of the Gene Therapy Market Report:

See the original post here:
Coronavirus' business impact: Gene Therapy Market 2019 By Advancements, Application, Challenges, Trends, Top Key Players, Growth & Forecast Till...

Global Antiaging Products and Services Market analysis report is a historical overview and all-inclusive study on the current & future market of the Healthcare industry. This market study has been analyzed and takes into account the CAGR of the market, valuation, volume, revenue including historical and forecast, sales (current and future), and other significant factors related to the global market. Antiaging Products and Services Market business document puts forward an in-depth assessment of each crucial aspect of the worldwide market that relates to the market size, market share, market growth factor, key vendors, revenue, top regions, industry trends, product demand, sales volume, capacity, cost structure & expansion in the market.

Request for Sample Copy or PDF Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-antiaging-products-and-services-market

Theglobal antiaging products and services marketis expected to reach USD 859.11 billion by 2025, from USD 347.58 billion in 2017 growing at a CAGR of 11.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Some of the major players operating in the globalantiaging products and services marketareChanel SA, GlaxoSmithKline Plc, Allergan Inc, Neutrogena Corporation, Procter & Gamble, Elizabeth Arden Inc, Johnson & Johnson, Orlane SA, Revlon Inc, Novartis International AG, Unilever PLC, Avon Products Inc, Woodridge Labs Inc, Beiersdorf, LOral SA, Merck & Company Inc, Christian Dior, Valeant Pharmaceuticals International, NeoStrata Company Inc, Bayer Schering Pharma AG, F. Hoffmann-La Roche Ltd among others.

Market Definition:Global Antiaging Products and Services Market

As the skin ages, it loses its natural elasticity and becomes thinner, more fragile and laxer, taking on a wrinkled appearance. In modern society, there is a great increase in the search for eternal youth and an insatiable appetite for methods which could turn back the clock. This has triggered an explosion in the antiaging industry. In addition, technological advances in medicine for the prevention and treatment of deadly diseases help to increase life expectancy.

The aging process of the skin generally has two kinds of forms: natural aging and light aging. There are various factors which directly affect intrinsic aging such as ethnicity, anatomic variations, hormonal changes, extrinsic aging, drugs, smoking and sunlight exposure. These aging conditions can be treated by the antiaging products such as UV absorbers, anti-wrinkle products, anti-stretch products, others and services and therapies. For anti-aging, the cosmetics are commercially available products that can be used to improve the appearance of the skin. People are constantly demanding for more effective products that can essentially beautify the appearance and has resulted in augmented basic science research and product development in the cosmetics industry.

According to news provided by Stempeutics Research Pvt. Ltd., in July 2015, Cipla (India) launched a new anti-aging product which uses human bio-active factors. The product was launched with a brand name Cutisera, developed by Stempeutics. This product will be used for reducing fine lines and wrinkles, lightening dark spots, evening skin tone, improving skin firmness and improving skin hydration.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-antiaging-products-and-services-market&raksh

Market Segmentation:Global Antiaging Products and Services Market

The global antiaging products and services market is segmented based on product, therapies and services and geographical segments.

Based on product, the market is segmented into UV absorbers, anti-wrinkle products, anti-stretch products and others.

Based on therapies and services, the market is segmented into eye-lid surgery, abdominoplasty, hormone replacement therapy, breast augmentation, liposuction, gene therapy, injectable skin, botox, telomere based therapy, rejuvenation and dermal fillers, sclerotherapy, anti-pigmentation therapy, hair restoration services and chemical peels.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Major Market Drivers and Restraints:

Key Developments in the Market:

Competitive Analysis:Global Antiaging Products and Services Market

The global antiaging products and services market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of antiaging products and services market for global, Europe, North America, Asia Pacific and South America.

Reasons to Purchase this Report

Customization of the Report

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-antiaging-products-and-services-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

See the article here:
Antiaging Products and Services Market Competitive Strategies and Worldwide Demand with Top Players Elizabeth Arden Inc, Johnson & Johnson,...

A gene therapy that eliminates the need for radical cystectomies (complete removal of the bladder) in a particular, aggressive form of bladder cancer is undergoing Priority Review by the U.S. Food and Drug Administration (FDA). It was developed by FKD Therapies Oy with the close collaboration of the Society of Urologic Oncology Clinical Trials Consortium in a novel industry/professional society partnership.

Originally, the therapy nadofaragene firadenovec (rAd-IFN/Syn3), since dubbed INSTILADRIN was developed in the lab of Colin P.N. Dinney, M.D., chairman, department of urology, division of surgery, University of Texas MD Anderson Cancer Center, Houston, and co-founder of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), which was critical in conducting the clinical trials.

As Dinney recalled, I developed this drug from preclinical to Phase I with Schering-Plough Corp. Then Schering was bought by Merck, which decided not to develop it.

That was around 2009, when the financial crisis was constraining research budgets and relegating many urologists to procedures.

To ensure that urologists retained awareness of and access to research opportunities, Dinney co-founded SUO-CTC, a network of approximately 400 academic and private practice urologists and 200 clinical sites. It works as an independent partner and consultant with biopharmaceutical companies to identify patients and sites for clinical trials, review clinical trial protocols, and meet with investigators and their collaborators to improve clinical trials.

This early, active involvement enables urologists to identify additional opportunities for companies while also expanding research opportunities for its urologist members. In addition to bladder cancer trials, the SUO-CTC also collaborates in partnership with pharmaceutical and biotechnology companies to develop and conduct trials for prostate cancer and renal cancer.

Its a very lean organization that offers enormous advantages to its pharma partners, Gennady Bratslavsky, M.D., told BioSpace. Its expertise encompasses many urologic sub-specialties including, but not limited to, sequencing and biomarkers, and insights from practicing physicians and academic experts. By providing this expertise early, we become an intellectual partner, which is a unique approach.

The development of nadofaragene firadenovec is a prime example of an effective collaboration between the SUO-CTC and pharma to develop a novel therapeutic that addresses an unmet need for patients with bladder cancer," Bratslavsky said.

When the SUO-CTC was formed, however, it started at ground zero.

We needed a trial to jumpstart the activity of the bladder cancer committee, and I had discussed nadofaragene firadenovec with the president of FKD Therapies Oy, Dinney said.

Not only did Dinney discuss his Phase I data, but he also discussed a particular patient. I had a patient with Alzheimers disease with high-grade non-muscle-invasive bladder cancer who had not responded to BCG therapy. His wife felt surgery was not a good solution because of his Alzheimers, Dinney said. He enrolled the man into a trial, and administered one of the higher doses. He remained disease-free until he died of Alzheimers four years later.

FKD licensed the therapy and Dinney negotiated for the SUO-CTC to have exclusive control of the trial sites. The organization recruited 13 sites from among its members for Phase II trials, and quickly enrolled patients. Larger Phase III trials also were recruited quickly and with favorable results.

"This treatment is truly a game-changer and adds a powerful new intravesical therapy for patients with Bacillus Calmette-Gurin (BCG) unresponsive bladder cancer," Dr. Michael Cookson, president of the Society of Urologic Oncology (SUO), said in a statement.

Specifically, INSTILADRIN is designed for patients with high-grade non-muscle-invasive bladder cancers. The therapy is an adenovirus vector-mediated interferon alfa-2b gene therapy. It was granted Breakthrough Therapy designation by the FDA. Industry watchers say it has the potential to compete with Mercks Keytruda, which was approved in January for the same condition.

Approximately 81,000 people inthe United Statesare diagnosed with bladder cancer every year, according to the American Cancer Society, making it one of the most common cancers. It also is one of the deadliest cancers, claiming nearly 18,000 lives in the U.S. this year alone.

The gene therapy is administered to patients via a catheter, directly into the bladder, once every three months. In trials, it helped the body produce high quantities of a protein that fights the cancer. In the Phase III trial, 53% of patients achieved a complete response as early as three months, and 24% at 12 months. In patients with papillary disease, 73% achieved high-grade recurrence free (HGRF) survival at three months and 44% at 12 months.

INSTILADRIN uses an adenoviral vector to deliver the gene to the cells of the bladder wall, where breaks down and releases its DNA including the interferon gene. That gene is taken into the nucleus and transcribed, ultimately resulting into the secretion of high quantities of interferon alfa-2b proteins being released into the microenvironment of the tumor.

Now, were waiting for approval from the FDA and looking at opportunities to expand indications. Discussions are ongoing, Dinney said. The SUO-CTC also is considering trials to introduce the drug earlier in the course of the disease, as well as including it in combination therapies. His own lab but, as yet, not the SUO-CTC is investigating a companion diagnostic for early applications.

FKD, for its part, led the development, manufacturing and regulatory submission efforts. Assuming the FDA approves INSTILADRIN, FKD plans to license the gene therapy to FerGENE for commercialization in the U.S. and to advance global development.

Here is the original post:
Game-Changing Gene Therapy a Joint Effort by Urologist Consortium and FKD Therapies - BioSpace

Everybody wants to be fit. But not everybody wants to put in the effort to get there.

Who has time to spend long hours at the gym and eating right is such a bore. What if we told you that you could get ripped without exercising and eating whatever you wanted.

RELATED:EXERCISE IS THE BEST WAY TO KEEP THE POUNDS OFF, SAYS NEW STUDY

This is whata team at Washington University in St. Louis medical school achieved with mice in test trials. They created a gene therapy that when given to mice allowed them to build muscle mass and reduce obesity even while eating a diet high in fat and not exercising.

How did it work? The therapytargeted a gene called FST, which makes a protein called follistatin. Follistatin blocks a protein called myostatin, which stops muscle growth to ensure muscles dont get too large.

The researchers injected a virus carrying a healthy FST geneintoeight-week-old mice. They then observed the mice over a period of 18 weeks.

What they found was nothing short of impressive. The mice's muscle mass and strength more than doubled and they experienced reduced damage related to osteoarthritis and less inflammation in their joints.

"Regardless of diet, mice receiving FST gene therapy were protected from post-traumatic OA and bone remodeling induced by joint injury. Together, these findings suggest that FST gene therapy may provide a multifactorial therapeutic approach for injury-induced OA and metabolic inflammation in obesity," wrote the researchers in their paper.

Last but not least, the researchers were worried that the muscle growth caused by the therapy could hurt the heart. However, the study revealed that the heart function and cardiovascular health of treated mice actually improved.

If the therapy can be adapted to work for humans both its appeal and its applications would be limitless. The research was published in Science Advances.

Here is the original post:
New Gene Therapy Promises You Will Get Ripped Without Stepping in a Gym - Interesting Engineering

PHENOMENAL WOMEN SCIENCE & RESEARCH

The San Diego Union-Tribune and the Womens Museum of California are celebrating a century of female achievement in San Diego to mark the 100th year of womens suffrage in America.

The second installment of this series pays tribute to pioneering female scientists and researchers who pushed boundaries in exploring our world and beyond and helped cultivate new generations of curious thinkers.

Spotlighted is Sally Ride, the first U.S. woman in space, who encouraged girls interest in science with her namesake educational program, Sally Ride Science, based at UC San Diego. Here are 11 other women in science and research you should know.

Margaret Burbidge

(U-T file)

A lot of people told Margaret Burbidge she was invading a mans world in the late 1930s when she took her first steps toward becoming an astronomer. She was undeterred even though many key telescopes were off-limits to women. Burbidge pushed through the sexism and became one of the most influential astronomers of her era, largely due to her insights about the chemical composition of stars. Her work helped scientists figure out how stars are made and earned her the nickname Lady Stardust. She also helped to develop the Hubble Space Telescope. And in 1962, she became a founding faculty member at UC San Diego, where she continued research that would later earn her the National Medal of Science. Burbidge died on April 5 at the age of 100.

Karen Nelson

(Howard Lipin/The San Diego Union-Tribune)

Karen Nelson was an early bloomer. At age 7, she joined fellow students in studying how nutrients and sunlight affect the growth of plants. The experiment stoked her interest in science. She went on to become a Cornell-trained physiologist who specializes in the study of the human microbiome the genetic material found in all of the micro-organisms that live in and on our bodies. Nelson led the first group of scientists in publishing the first major paper on the human microbiome. The paper spotlighted an obscure area of research that is now regarded as indispensable to understanding and treating everything from diabetes to multiple sclerosis to depression. Nelson today serves as president of the J. Craig Venter Institute, the renowned research center in La Jolla.

The UC San Diego graduate floated out of an airlock and into history in October as a member of the first all-female team of spacewalkers. The 42 year-old astronaut achieved the fete from the International Space Station, during a six-month mission in which she also conducted research thats meant to help astronauts stay safe and healthy on trips to the moon and Mars. Meir also became a popular host of space-to-Earth broadcast interviews, including an especially poignant one with TV host Stephen Colbert. And she appeared on camera to give earthlings who were sheltering at home from the coronavirus lots of advice about how to live in isolation. Her future could be even brighter she is among the astronauts NASA will consider as crew members for missions to the moon.

Ellen Ochoa

(Cindy Lubke Romero/The San Diego Union-Tribune)

Theres a word that often appears immediately after Ellen Ochoas name: first. In 1991, she became the worlds first Hispanic female astronaut. Two years later, she became the first Hispanic woman to travel in space, streaking into orbit aboard the shuttle Discovery. In 1999, she was a member of the first shuttle crew to dock with the International Space Station. In 2013 Ochoa, who grew up in La Mesa and graduated from San Diego State University, became the first Hispanic to be appointed director of NASAs Johnson Space Center. In 2017, she was inducted into the U.S. Astronaut Hall of Fame. A year later, she retired from NASA, capping a career that spanned nearly three decades.

Maria Goeppert-Mayer

(Evening Tribune)

When it was founded in 1960, UC San Diego quickly hired a handful of renowned professors to signal other faculty that La Jolla was the place to be. The first recruits included Maria Goeppert-Mayer, a German-born theoretical physicist whose discoveries about the nucleus of atoms would help revolutionize everything from weaponry to power generation. Her contribution earned her a share of the 1963 Nobel Prize in physics. She was the first woman in the U.S. to win that prize. The San Diego Union-Tribune responded with a now-infamous headline: S.D. Mother Wins Nobel Physics Prize. Fifty-five years would pass before another woman won the Nobel in physics.

Olivia Graeve

(Courtesy of UC San Diego)

When astronauts return to the moon, they may be flying in a spacecraft made safer by Olivia Graeve. The UC San Diego engineer designs new materials that are meant to withstand extreme environments. She developed and tested an extraordinarily strong type of steel, providing a possible material for everything from spacecraft to body armor. The work occurs at the Cali-Baja Center for Resilient Materials and Systems, which Graeve founded after she became UCSDs first Latina engineering professor. In the summer, the Tijuana native also brings students from Mexico and the U.S. to campus to conduct research, helping cultivate new generations of engineers.

Flossie Wong-Staal

(Koji Sasahara/AP)

Its impossible to count how many lives shes saved, but the number is enormous. Flossie Wong-Staal helped identify the cause of AIDS in 1983 while working at the National Cancer Institute. A short time later, she became the first scientist to clone HIV, then finished mapping the virus genetically. In 1990, Wong-Staal joined the UC San Diego faculty, doing landmark research that has helped fight HIV/AIDS. She also helped turn UCSDs Center for AIDS Research into a research power, and greatly advanced the field of gene therapy. The Chinese-American virologist retired from UCSD in 2002 but has remained active in science and was inducted into the National Womens Hall of Fame in 2019.

Ayana Elizabeth Johnson

(Evan Agostini/Invision/AP)

Not long ago, the wondrous Caribbean island of Barbuda did little to protect its coral reefs and manage its fish populations. Today it does a great deal through programs that Ayana Elizabeth Johnson helped to shape after she earned a doctorate at UC San Diegos Scripps Institution of Oceanography. It was a first step in her rapid rise as an influential voice in sustainable fishing and ocean conservation. Johnson went on to found and lead Ocean Collectiv, a La Jolla conservation consultancy. She also founded the Urban Ocean Lab, a think tank that helps coastal cities. And she played a key role in organizing the 2017 March for Science, which drew more than 1 million participants worldwide.

Balboa Park is so lush its hard to believe it was once a bland patch of land. Many people infused it with life. But none were more important than Kate Sessions, a botanist and horticulturalist who leased part of the park as a growing field in the late 1800s. Sessions planted a variety of trees, ranging from oak to cypress to eucalyptus. She also brought in jacaranda, and helped found the San Diego Floral Association. Her work earned Sessions the nickname Mother of Balboa Park. The honor was about more than beauty. Sessions also studied plants and chronicled how they grew and changed, bringing her worldwide attention in the scientific community. In 1939, the year before she died, the American Genetic Association honored Sessions with the Frank N. Meyer medal, one of the most coveted honors in plant genetics.

Shirley Meng

(David Baillot/UCSD)

Everyone knows that batteries die. But were you aware that they first become sick? Thats the word that Shirley Meng uses to describe what happens when batteries stop holding a charge. It is a poorly understood process. But Meng has been making important discoveries about the phenomenon at UC San Diego, where she is director of the Sustainable Power and Energy Center. Meng, a nano-engineer, specializes in creating new tools and techniques for visualizing, in real-time, whats happening as a battery fails. Her work is meant to improve everything from smartphone service to the range of self-driving cars. Meng who is known as the battery doctor also founded Super 8 Technologies, a company that is developing battery technology that could be used by the military and in space exploration.

Carol Padden

(Sandy Huffaker)

Some linguists used to pointedly question whether American Sign Language, or ASL, is a genuine language. Padden helped establish that ASL is not only legitimate, but that it is a very precise, complex and expressive way of communicating. Padden, who is deaf, has done similar work on Al-Sayyid Bedouin Sign Language. Shes made her contributions as a linguistics researcher and communications professor at UC San Diego. She also is dean of the Division of Social Sciences, UCSDs largest program. In 2010, Padden was honored for her work by being named a MacArthur Genius Fellow. She continues to operate a research lab, something rarely done by high-ranking university administrators.

Sources: UC San Diego, San Diego State University, NASA, J. Craig Venter Institute, Wikipedia, MacArthur Foundation, New York Times, Los Angeles Times, San Diego Union-Tribune

Read the original post:
Phenomenal San Diego women in science and research - The San Diego Union-Tribune

PharmaSphere: Emerging Biotechnologies-Gene Therapy market gives us the acute prediction regarding sales and trends:The current report focuses on the impact of Covid-19 on PharmaSphere: Emerging Biotechnologies-Gene Therapy market industry. This report covers all the important areas like how the key players are enhancing their activities for their survival in the worldwide PharmaSphere: Emerging Biotechnologies-Gene Therapy market business. Graphs and flowcharts are being used for analyzing the information to be acceptable.

Key player focused on this market are: Advantagene, Amarna Therapeutics, AnGes MG, Inc., Applied Genetic Technologies Corporation, AskBio, Avalanche, Bluebird bio, Celladon Corporation, Dimension Therapeutics, American Gene Technologies International Inc,

Download Special samples With the effect of COVID19@: https://www.regalintelligence.com/request-covid19-global-insights/88714

PharmaSphere: Emerging Biotechnologies-Gene Therapy research study depicts the constantly changing trends and growth in the market with valued CAGR (compounded annual growth rate) in their forecast including all the factors responsible for the changed performance, growth evaluation and profitability in the market business.

Key points on which report focuses are:

Providing acute information.

Professional study for the period 2020-2023a.

Details of upstream raw materials, downstream demand and production value.

Market growth factors.

Market segmentation:

Basis of segmentation: Types of products, application and region.

By Type: Type 1, Type 2

Significant PharmaSphere: Emerging Biotechnologies-Gene Therapy application along with their consumption details: Application 1, Application 2

The time period to estimate the market size:

The history year 2015-2019

The base year 2019

Estimated 2020

Forecast 2020-2023a

Segmentation is concerned with the market share, revenue and growth rate etc. The report shows the high growth period of PharmaSphere: Emerging Biotechnologies-Gene Therapy markets and how can the segments grow during the forecast period.

Ask For Discount@ https://www.regalintelligence.com/check-discount/88714

The main objective of PharmaSphere: Emerging Biotechnologies-Gene Therapy market report is future forecasting, determining opportunities, challenges and threats, making suitable business plans, analyzing market competition and getting advantages and helps in decision making.

This report answers to questions like: Growth rate and market size in 2023a.

Effecting factors, opportunities, challenges, threats of the global PharmaSphere: Emerging Biotechnologies-Gene Therapy market. Competing products.

What M&A activity has taken place in past years.

Table of Contents:

Chapter 1 About the PharmaSphere: Emerging Biotechnologies-Gene Therapy Industry

1.1 Industry Definition and Types

1.2 Main Market Activities

1.3 Similar Industries

1.4 Industry at a Glance

Chapter 2 World Market Competition Landscape

2.1 PharmaSphere: Emerging Biotechnologies-Gene Therapy Markets by Regions

Market Revenue (M USD) and Growth Rate 2015-2023a

Sales and Growth Rate 2015-2023a

Major Players Revenue (M USD) in 2020

2.2 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market by Types

2.3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market by Applications

2.4 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis

2.4.1 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Revenue and Growth Rate 2015-2020

2.4.2 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Consumption and Growth rate 2015-2020

2.4.3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Price Analysis 2015-2020

Chapter 3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market share

3.1 Major Production Market share by Players

3.2 Major Revenue (M USD) Market share by Players

3.3 Major Production Market share by Regions in 2020, Through 2023a

3.4 Major Revenue (M USD) Market share By Regions in 2020, Through 2023a

Chapter 4 Supply Chain Analysis

4.1 Industry Supply chain Analysis

4.2 Raw material Market Analysis

4.2.1 Raw material Prices Analysis 2015-2020

4.2.2 Raw material Supply Market Analysis

4.2 Manufacturing Equipment Suppliers Analysis

4.3 Production Process Analysis

4.4 Production Cost Structure Benchmarks

4.5 End users Market Analysis

Get Full Report@ https://www.regalintelligence.com/buyNow/88714

Conclusion: This report covers all the necessary information like market landscapes production and consumption analysis, demand and supply analysis, market growth analysis with future predictions and SWOT and PEST analysis, investment and return analysis.

Original post:
PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and...

Logan Howard

Under normal circumstances, graduating seniors gather on Old Campus, clad in zany headwear and surrounded by newly-planted tulips, to partake in the storied traditions that form Class Day. This year, the event was not one day, but seven.The week of reflections and remarks from members of the class of 2020, faculty and alumni culminated with a speech from Jean Bennett 76 on Sunday afternoon.

Seniors received a Class Day care package including tassels, a class anthology and a Yale pin, among other items earlier this week. The Class Day committee, composed of five seniors Sarah Geach 20, Michelle Hu 20, Ananya Indwar 20, Nathan Isaacs 20 and Calvin Schwartzberg 20 encouraged graduates to make masks for their communities rather than the hats that normally characterize the celebration. The past six days have featured remarks from students, faculty members and alumni. On the seventh, Bennett urged graduates to seize the current moment as an opportunity for unity and progress.

We are all now faced with an opportunity for reflection, Bennett said. The world has been so divided, but for once our stress is the same stress something that binds us together.

This terrible experience has created new opportunities and your class will shape things to come. This event will galvanize you all to put your talents, expertise, imagination and passions to good use. You have a huge opportunity to reset to reengineer our world.

Bennett is a professor of ophthalmology at the University of Pennsylvanias Perelman School of Medicine. Her research into retinal diseases led her to develop Luxturna a gene therapy to treat Leber congenital amaurosis, a rare heritable disease that often results in blindness. Luxturna was the first gene therapy ever approved by the Federal Drug Administration for use in humans.

Bennett grew up in New Haven, toured with the Yale Symphony Orchestra in high school and worked in the Universitys biology labs before enrolling as an undergraduate. Reflecting on her time in the Elm City, Bennett recalled anti-Vietnam war movements, the Black Panther trials and a 1:50 ratio of women to men in the sciences.

She drew a connection between researching HIV/AIDS as a Yalie and todays global scientific movement to understand SARS-COV-2.

We do not want to have a future overshadowed by coronavirus, Bennett said. I know that [at] some point we will be able to get back to the projects we put on hold. In the meantime, each of us can try to figure out how to apply our skill the best or to do what we can to contribute.

The Sunday ceremony closed with a performance of Bright College Years by the Yale Bands and Glee Club.

In the days leading up to Bennetts speech, seniors offered their thoughts about the past four years. Joy Qui 20 shared a serious reflection on Tuesday, challenging the idea that all Yale students share fundamental parts of their college experience and the idea that a strong common bond is a positive notion.

The alternative to believing that we share nothing in common would be to believe that Yale is so seductive that four years here is enough to hammer parts of our identities into shapes completely indistinguishable from one another, Qui said.

In a comedic reflection the following day, Simon Fraser 20 and Oscar Lopez 20 congratulated their classmates on something they do all share: the ugliest diploma in America.

We left Yale too early and we had different Yale experiences, Lopez said. Some of us never had the tuna tartar at Harvest.

And some of us still think Shades of Yale is a Facebook group for overhead insults on campus, Fraser responded.

The next several days featured recreations of traditional Old Campus activities such as Vincent Vaughnss 20 Ivy Ode, An Ode to Fight, delivered with an ivy plant in the frame. The class of 2020 will plant their sprig of ivy on Old Campus when it is safe to return. Dean Marvin Chun saluted graduating seniors on their accomplishments, seniors submitted photos and memories from the past four years for a class slideshow and scores of alumni offered a toast to the class of 2020 in video form.

The University is planning to host an in-person celebration of the graduates at a later date.

Mackenzie Hawkins |mackenzie.hawkins@yale.edu

Read the original post:
Virtual Class Week concludes with Bennett's message: You have a huge opportunity to reset - Yale Daily News

Doctors in Southern California are working with researchers in Arizona to better understand the bodys sometimes bizarre immune response to COVID-19 an antibody onslaught that may kill the patient, rather than kill the virus.

The nonprofit Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is peering into specific proteins on the virus to see how they react with different antibodies a high-resolution view that might guide treatment, testing and vaccine development.

The hypothesis is that antibodies can make things worse, and thats whats killing some people, said John Altin, assistant professor in TGens infectious-disease branch. We want to understand how that might be different from an immune response that protects somebody.

As many critically ill patients are treated in clinical trials with convalescent plasma therapy that is, injecting antibodies from recovered COVID-19 patients into those who are very ill, in hopes of triggering protective immune responses its imperative to understand whats behind the differing reactions.

Usually, antibodies provide protection, but there may be a bit of an exception with this virus, Altin said. That is a serious concern.

To that end, TGen and the Center for Gene Therapy at City of Hope are cooperating on a COVID Immunity Study that aims to collect blood from COVID-19 survivors.

The researchers will analyze your blood and profile your immune memory, the study consent form explains.

Participants can use the TGen kit at home. Theyll get a study kit by mail and collect one small spot blood sample, via a finger-prick device, for two consecutive weeks. Then theyll mail the study kit back to TGen.

About 500 people are expected to participate through the course of the study, and researchers may reach out for additional samples, and/or with additional questions, to see how immune memory changes over time.

Participants must be U.S. residents, at least 18 years old, have tested positive for COVID-19, and then recovered. For more information, see https://covidimmunity.org/.

This will help us learn more about how, when and why we produce antibodies in response to a COVID-19 infection, said David Engelthaler, director of TGen North, in a prepared statement. One class of antibodies tackles the infection first, and then another comes in to finish the job. Knowing when these different immune responses occur, and how long they last, could help us understand if some patients gain a certain degree of immunity against reinfection. We need to know how that works.

While large-scale clinical trials involving convalescent plasma are under way all over the nation, this study aims not to treat the disease, but to better understand the mechanisms behind it.

TGen describes its approach as a high-resolution view of the antibody response. It seeks to not only map the viruss proteins in detail, but to also see which parts of those proteins are targeted by antibodies.

Our approach will not only tell you which proteins arebeing targeted, but also be able to tell which regions of each protein are being targeted, Altin said in a statement. Each protein can be recognized by many different types of antibodies. By looking at this level of detail, we then could see elements of the antibody response that others might be missing.

TGen hopes to tease out subtle differences that can help develop therapies, vaccines and better antibody testing.

Others are looking at responses to the entire protein. Our approach is a little different. When we look at the antibody response, we divide it up into thousands of pieces. Theres potential for that to tell us what a beneficial and un-beneficial response might look like, Altin said.

John Zaia, director of the Center for Gene Therapy at City of Hope, is working with TGen, and has other COVID-19-related projects happening as well.

Zaia is leading a research project at City of Hope, in collaboration with Altins lab, that could lead to development of a COVID-19 virus antibody neutralization test, which would quantify antibodies.

Zaia also has received a $750,000 grant from the California Institute for Regenerative Medicine for a clinical study on the use of blood plasma as a potential treatment for COVID-19.

Theyre doing what you could call qualitative and quantitative measurements of the nature of the antibody what does it actually bind to? Zaia said. The virus has this surface protein, the spike protein, but there are also other things the immune system might be seeing. It might be focused on one or more parts of the spike.

The CIRM project will focus on finding plasma donors to determine if theres any correlation between the outcome in the sick patient who received the plasma and the specific antibody that went in. It will focus on under-served areas.

Duarte-based City of Hope was founded in 1913 and is a founding member of the National Comprehensive Cancer Network. It has many sites throughout Southern California, and is investing $1 billion to establish clinics and a cancer center in Orange County. A clinic opened in Newport Beach in January, and a hospital dedicated to cancer treatment and research is slated for Irvine.

On the forefront of science, new discoveries are made every day and so much is still unknown.

I think the FDA said it best: Theres no way that one group could solve all the problems, do all the testing that needs to be done, Zaia said. The whole field is so new.

Theres a balance that must be struck between moving quickly and moving carefully, Altin said. We should know a lot in the next three months about how the antibody response looks, he said. Vaccine development will take much longer.

The rest is here:
Why does immune response to coronavirus save some, kill others? - OCRegister

In wide-ranging congressional testimony, the ousted head of an agency at the center of the federal governments Covid-19 vaccine and treatment response criticized the Trump administration for a slow-footed federal response that could resound throughout the course of the pandemic.

I believe we could have done better, Rick Bright, former chief of the Biomedical Advanced Research and Development Authority (BARDA), told a House subcommittee. We dont have the right leadership for this response and we dont have the right plan for this response.

Bright, who has headed BARDA since 2016, was removed from his post in April. Several days later, he accused HHS of reassigning him because he opposed efforts to put significant funds behind Covid-19 drugs not supported by data, including the anti-malarial hydroxychloroquine. Bright subsequently filed a whistleblower complaint detailing a long history of political interference at the agency, setting up a much-anticipated congressional hearing on Thursday.

Thursday morning, in the leadup to Brights testimony, President Trump dismissed Bright on Twitter as a disgruntled employee who he had never heard of. And HHS released a lengthy rebuttal to the whistleblower complaints, setting the stage for some of the line of questioning Republicans used during the hearing.

Mr. Bright has not yet shownup for work, but continues to collect his $285,010 salary, while using his taxpayer-funded medical leave to work with partisan attorneys who are politicizing the response to COVID-19, a spokesperson said in an emailed statement. His whistleblower complaint is filled with one-sided arguments and misinformation.

The Office of Special Counsel, a government watchdog, however, preliminarily determinedtoday there was evidence backing Brights claims and that he should be reinstated.

Unstrapping a black cloth mask to testify, Bright pointed to mismanagement at HHS from the early days of the pandemic. He said he tried to secure a sample of the virus in January to help expedite the development of vaccines, treatments and diagnostics, but the agency was not able to acquire one until February. He attempted to get funding for vaccines and countermeasures in his first meeting with HHS secretary Alex Azar, he said, but Azar was puzzled by his question, he said, and over the months his continued calls for urgency led to him being shut out.

I was told that my urgings caused a commotion and I was removed from those meetings, Bright said.

He pointed to emails, mentioned from his whistleblower complaint, he received in January from Mike Bowen, the head of mask manufacturer Prestige Ameritech, offering N95s and warning the US had insufficient domestic supply.

He said were in deep shit, the world is, and we need to act and I pushed that forward to the highest levels I could in HHS and got no response, Bright said. From that point I knew we were going to have a crisis.

In their statement, HHS said Bright was not responsible for masks and said Brights assumption that others were not concerned with and working on various workstreams related to COVID-19 preparedness is bizarre and false.

Although Brights complaint pinned his ouster on his opposition to hydroxychloroquine, journalists pointed out that Brights signature was on the documents authorizing the emergency use of the pill for Covid-19 patients. In their statement, HHS called Bright the sponsor of the hydroxychloroquine effort who celebrated when the government was able to secure the supply.

Bright told the House that he had been directed to file those authorizations by the Trump administration. He argued the supply was necessary for clinical trials but not outside it. Alongside other government scientists, he said, he had worked to push back on administration efforts to set up an expanded access protocol by which people including those who hadnt tested positive to Covid-19 could have access to the potentially dangerous drug outside of a hospital. We had to come up with an alternate solution that the administration would accept, he said.

While initially successful, Bright said, he then learned of and spoke out against a subsequent government plan to flood New York and New Jersey with the anti-malarial, leading to his ouster.

That was the straw that broke the camels back, Bright recalled, and expedited my removal.

Turning toward more recent controversy, Bright said a chaotic government response has endangered patients and could impede the response going forward. Over the week-and-a-half since the FDA authorized the use of remdesivir as the first drug shown to have efficacy against Covid-19, doctors have sharply criticized the government for how theyve distributed the Gilead antiviral, with no clear criteria announced and some hospitals with larger numbers of patients unable to secure a supply.

Bright was no longer at BARDA when remdesivir was authorized, but he said no plan had been put in place to prepare for when it was.

There was never action taken on the urgency to come up with a plan for acquisition of limited doses, Bright said, nor to distribute the limited doses of remdesivir.

Now, Bright said, similar problems loom for potential vaccines, once theyre shown to work. Although BARDA and the leading vaccine companies have put significant funds into scaling up manufacturing, an approved vaccine will still come in batches rather than all at once, posing a need to equitably distribute the doses until they are available. Bright revealed that the government had secured access to some of those doses with their funding agreements, but he said theres little plan for how to give them out.

Its going to be a limited supply, Bright said. We need to have a strategy and a plan in place now. We dont have that yet and it is a significant concern.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

Read more:
Rick Bright details mismanaged pandemic response, warns of drugs, vaccine supply problems down the road; HHS pushes back - Endpoints News

Trying to hack fitness is a multi-million-dollar industry; weve all seen at least one ad featuring a purported miracle product that claims it can make people lose weight and look greatwithout even trying. From low-effort exercise machines to strange-ingredient diets to fat-burning belts and bands, theres no shortage of attempts to make it easy to be fit.

A gene therapy trial performed on mice may foreshadow yet another way to hack fitness. In a study done by a team at Washington University in St. Louis medical school, mice quickly built muscle mass and reduced obesity after receiving the therapy, even while eating a diet high in fat and not exercising. The results were published last week in a paper in Science Advances.

Sound appealing? Heres how it worked.

The gene targeted was FST, which is responsible for making a protein called follistatin. In humans and most other mammals, follistatin helps grow muscle and control metabolism by blocking a protein called myostatin, which acts to restrain muscle growth and ensure muscles dont get too big.

The researchers injected eight-week-old mice with a virus carrying a healthy FST gene (gene therapy involves adding healthy copies of a gene to cells, usually using a virus as a deliveryman).

Over a period of 18 weeks, or about 4 months, the team observed that the muscle mass of the treated mice more than doubled, as did their strength level. They also experienced reduced damage related to osteoarthritis, less inflammation in their joints, and had healthier hearts and blood vessels than mice that didnt receive the gene therapyeven though all the mice ate the same high-fat diet and did the same amount of exercise.

Going into the study, the researchers worried the muscle growth catalyzed by the gene therapy could harm the heart, mainly through thickening of the hearts walls. Surprisingly, though, heart function and cardiovascular health of the treated mice actually improved. In subsequent studies, the team will continue to monitor the treatments effect on the heart, as complications could emerge over time.

Talk about a fitness hack; imagine being able to build muscle and maintain a healthy metabolism while lounging on the couch eating burgers and fries. There have been similar studies to replicate the effects of exercise by commandeering the genetic instructions that control the way cells interact with proteins; though various exercise pills have successfully mimicked the effects of regular cardiovascular activity in mice, scientists still dont fully understand how, at a molecular level, exercise has the effects it does on the human body.

This may change in the next couple years, though; a National Institutes of Health consortium called the Molecular Transducers of Physical Activity is in the midst of an in-depth study on the molecular effects of exercise on tissues and organs in 3,000 people.

If the muscle-building gene therapy eventually reaches a point where it can be used in humans, though, the research team isnt viewing it as a quick-fix health hack. Rather, it would be used to help get people with conditions like muscular dystrophy or severe obesity to a baseline from which they could adopt tried-and-true muscle-building practices like weight lifting or physical therapy.

In cases of severe obesity or muscle loss, it is extremely difficultif not impossibleto lose weight or improve muscle strength through normal exercise and diet, said Farshid Guilak, orthopedic surgery professor and director of research at Shriners Hospitals for Children in St. Louis. The goal of this study was to show the importance of muscle strength in overriding many of the harmful effects of obesity on the joint.

If every condition, process, and trait in our bodies is tightly linked to our genes, its conceivable that almost any aspect of our health could be manipulated using gene therapy and related tools. Maybe one day there will indeed be a pill we can take or a shot we can get to give us svelte, muscular bodies without any of the effort.

The fact that this would ruin the pleasure and satisfaction of a good workout is another conversationand one not everybody would be interested in having. But even if genetic or chemical exercise-replacement tools become safe to use in humans in the foreseeable future, theyll likely be limited, at least at first, to those who need them due to debilitating health conditions.

That saidfor the time being, keep hitting the treadmill, the weight room, or your other off-the-couch, effort-intensive workout of choice.

Image Credit: Aberro Creative from Pixabay

See the article here:
Forget ExerciseThese Mice Got Ripped With Gene Therapy - Singularity Hub

In 2019, the Philadelphia region was home to just under 5,000 cell and gene therapy jobs. But in 2029, we could be looking at more than doubling that figure, a report commissioned by three regional economic and research groups found recently.

The Chamber of Commerce for Greater Philadelphiasregional CEO Council for Growth, the University City Science Center, and University City Districts West Philadelphia Skills Initiative banded together with support from the Lenfest Foundation to take a closer look at the state of jobs in cell and gene therapy, along with the industrys future.

The project, titled the Cell and Gene Therapy and Connected Health Workforce Analysis, found that cell and gene therapy jobs will likely grow between 35% to 94% in the next 10 years with mid-range growth estimates and as much as 54% to 136% with high-range growth estimates.

So, a decade from now, we could see anywhere between the low-end projection of 7,608 jobs and the high-range projection of 11,274 jobs.

Surveys, interviews and focus groups with academic researchers, industry and human resources experts, and workforce development organizations informed the report, and helped develop potential scenarios, the Science Center said in a release.

The objective of the study was to characterize the current landscape, assess growth scenarios and project future talent needs for these two particularly dynamic industry subsectors, said Saul Behar, the Science Centers SVP for advancement and strategic initiatives.

The findings confirm that the region is on track to become a leader in the space, and that Philly is positioned to recruit and train thousands of new employees over the next few years, Behar said.

Those jobs will likely pull from the wealth of pharma companies in the region, but will still require some extra training, the report said. Roles like manufacturing technicians, particularly within contract manufacturing organizations, might rise in demand as tech innovations allow for growth in therapy manufacturing.

And as cell and gene therapy firms grow, there will be opportunities for a diverse workforce from multiple education and skill levels, and firms will also require workers with backgrounds in finance, information technology, legal services, human resources and general operations.

(Ensuring that jobs in the biotech and cell and gene therapy space are not just for highly educated folks has been the focus of recent efforts of a handful of organizations across the city, including the West Philadelphia Skills Initiative; find a deeper dive into that initiative here.)

And to attract talented workers, startups must be able to explain their distinct value proposition offered by working in an emerging, fast-growing industry, the report said.

The study was conducted before the coronavirus pandemic began in the region, but those collaborating on the study think that it will actually help spur innovation in the region.

The search for new cures, therapies and treatments, as well as the role of data analytics, and the importance of connected health are top of mind and will continue to be a core strength of and competitive advantage for our region, said Claire Marrazzo Greenwood, executive director of CEO Council for Growth.

View post:
Study: The Philly region is on track to add thousands more cell and gene therapy jobs in the next 10 years - Technical.ly

A recent market intelligence study on the Gene Therapy market2020incorporates proprietary techniques and assessment tools to screen the Gene Therapy market for the forecast period, 2020-2026. Additionally, valuable insights pertaining to the market size, share and growth rate of Gene Therapy market offers a greater chance of success for all business owners, products, and new technology.

Major Gene Therapy market players covered by this research report are:

Sibiono GeneTech,Advantagene,Spark Therapeutics,Shanghai Sunway Biotech Co. LtdBluebird Bio,UniQure NVAvalanche Bio,Celladon,Sangamo,Dimension Therapeutics

Request for Sample Report @ https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #request_sample

Incorporated with Info-graphics, charts, tables and figures, this research report Gene Therapy Market Size, Type Analysis, Application Analysis, End-Use Industry Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2020- 2026is based on a wide-ranging research of the entire Global market and covering all its sub-segments through comprehensively thorough classifications. Insightful analysis and valuation are created from superior primary and secondary information sources with data and information derived from industry specialists across the value chain. The report provides historical market data for 2015-2019, base year estimates for 2020, and forecasts from 2020 to 2026.

Research Methodology:

The research report provides trustworthy primary and secondary research. It also depends on the most recent analysis techniques to organize extremely detailed and accurate research studies such as this Gene Therapy Market. It uses data triangulation, top-down and bottom-up approaches, and advanced Gene Therapy Market research processes to come out with comprehensive and industry-best market research reports.

Classification by Type is as follows:

Viral vectorNon-viral vector

Classification by Application is as follows:

Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

Inquire Here For More Details Or Custom Content @ https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #inquiry_before_buying

Gene Therapy Market 2020 Dynamics:

Drivers:(Developing regions and growing markets)

Boundaries:(Regional, Key Player facing Issues, Future Barriers for growth)

Opportunities:(Regional, Growth Rate, Competitive, Consumption)

Regional Segmentation:

TOC of Gene Therapy Market 2020 Report Includes:

View Report TOC In detail @ https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #table_of_contents

Visit link:
Global Gene Therapy Market Outlook, Opportunities, Key Players, Growth, Competitive Landscape, Trends and Forecast by 2026 - Cole of Duty

Moncef Slaoui stepped off Modernas board of directors on Friday and pivoted straight into the high profile role heading the Trump administrations Project Warp Speed, where hell be in charge of accelerating Modernas and others vaccines to a rapid release for a pandemic weary world.

The news became official mid-day Friday after numerous reports earlier that he had been picked off the short list of candidates.

Slaouis role on Modernas board earned a compensation package valued at $490,000 last year, something consumer advocates quickly fixed on as a conflict of interest. Its unlikely that critics will be satisfied by Slaouis resignation, though Moderna has already done quite well for itself without any added help from Slaoui. The biotech has benefited extensively from major support from BARDA and the NIH and will continue to enjoy close contacts in Washington, including at the FDA.

As the lead developer in the US of a new vaccine, Moderna also offers the White House a Boston-based company that can potentially provide a US hero to resolve the pandemic. So its likely Trumps favorite player with or without Slaouis involvement.

Moderna CEO Stphane Bancel is part of a small band of vaccines execs who believes its possible to do something that would have been considered impossible at the beginning of the year: hustle a new vaccine straight through a Phase I-III program in a matter of months and come up with just enough pivotal efficacy and safety data to start distribution in the fall.

While billions of people eagerly want that, theres also been some significant pushback from a variety of experts in the field who wonder if its really feasible to be able to field a Covid-19 vaccine in less than 2 years in itself something of a miracle in a sector where development can take years and sometimes decades.

Slaouis position will have already been molded by his board post. And it will fit neatly into the administrations own view that they can make it happen. Speaking at the White House today, he mentioned seeing unpublished data presumably Modernas that suggested success is close at hand, according to Politico.

These data made me feel even more confident that we will be able to deliver a few hundred million doses of vaccine by the end of 2020, he said.

We wont have long to wait.

See the original post:
Moncef Slaoui pivots from Moderna's board to the helm of Project Warp Speed. His task: Overnight success - Endpoints News

The research study on Global Personalized Gene Therapy Treatment market 2019 presents an extensive analysis of current Personalized Gene Therapy Treatment market size, drivers, trends, opportunities, challenges, as well as key Personalized Gene Therapy Treatment market segments. Further, it explains various definitions and classification of the Personalized Gene Therapy Treatment industry, applications, and chain structure.In continuation of this data, the Personalized Gene Therapy Treatment report covers various marketing strategies followed by key players and distributors. Also explains Personalized Gene Therapy Treatment marketing channels, potential buyers and development history. The intent of global Personalized Gene Therapy Treatment research report is to depict the information to the user regarding Personalized Gene Therapy Treatment market forecast and dynamics for the upcoming years. The Personalized Gene Therapy Treatment study lists the essential elements which influence the growth of Personalized Gene Therapy Treatment industry. Long-term evaluation of the worldwide Personalized Gene Therapy Treatment market share from diverse countries and regions is roofed within the Personalized Gene Therapy Treatment report. Additionally, includes Personalized Gene Therapy Treatment type wise and application wise consumption figures.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

After the basic information, the global Personalized Gene Therapy Treatment Market study sheds light on the Personalized Gene Therapy Treatment technological evolution, tie-ups, acquisition, innovative Personalized Gene Therapy Treatment business approach, new launches and Personalized Gene Therapy Treatment revenue. In addition, the Personalized Gene Therapy Treatment industry growth in distinct regions and Personalized Gene Therapy Treatment R;D status are enclosed within the report.The Personalized Gene Therapy Treatment study also incorporates new investment feasibility analysis of Personalized Gene Therapy Treatment. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Personalized Gene Therapy Treatment market.

Global Personalized Gene Therapy Treatment Market Segmentation 2019: Personalized Gene Therapy TreatmentThe study also classifies the entire Personalized Gene Therapy Treatment market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Personalized Gene Therapy Treatment market is characterized by the existence of well-known global and regional Personalized Gene Therapy Treatment vendors. These established Personalized Gene Therapy Treatment players have huge essential resources and funds for Personalized Gene Therapy Treatment research as well as developmental activities. Also, the Personalized Gene Therapy Treatment manufacturers focusing on the development of new Personalized Gene Therapy Treatment technologies and feedstock. In fact, this will enhance the competitive scenario of the Personalized Gene Therapy Treatment industry.

The Leading Players involved in global Personalized Gene Therapy Treatment market are:

By Therapy (Targeted Treatments and Pharmacogenomics),By Application (Breast Cancer, Brain Cancer, Colorectal Cancer, Certain Childhood Cancers, Gastrointestinal Stromal Tumor, Kidney Cancer, Leukemia, Lymphoma, Melanoma, Lung Cancer, and Multiple Myeloma)By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

Worldwide Personalized Gene Therapy Treatment Market Different Analysis:Competitors Review of Personalized Gene Therapy Treatment Market: Report presents the competitive landscape scenario seen among top Personalized Gene Therapy Treatment players, their company profile, revenue, sales, business tactics and forecast Personalized Gene Therapy Treatment industry situations. Production Review of Personalized Gene Therapy Treatment Market: It illustrates the production volume, capacity with respect to major Personalized Gene Therapy Treatment regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Personalized Gene Therapy Treatment Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Personalized Gene Therapy Treatment target consumer. Supply and Demand Review of Personalized Gene Therapy Treatment Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Personalized Gene Therapy Treatment product type. Also interprets the Personalized Gene Therapy Treatment import/export scenario. Other key reviews of Personalized Gene Therapy Treatment Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Personalized Gene Therapy Treatment players, potential consumers and suppliers. Also, the strengths, opportunities, Personalized Gene Therapy Treatment market driving forces and market restraints are studied in this report.

Highlights of Global Personalized Gene Therapy Treatment Market Report:* This report provides in detail analysis of the Personalized Gene Therapy Treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Personalized Gene Therapy Treatment market. * This study also provides key insights about Personalized Gene Therapy Treatment market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Personalized Gene Therapy Treatment players. * It profiles leading players in the worldwide Personalized Gene Therapy Treatment market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Personalized Gene Therapy Treatment report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Personalized Gene Therapy Treatment marketing tactics. * The world Personalized Gene Therapy Treatment industry report caters to various stakeholders in Personalized Gene Therapy Treatment market. That includes investors, device manufacturers, distributors and suppliers for Personalized Gene Therapy Treatment equipment. Especially incorporates government organizations, Personalized Gene Therapy Treatment research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Personalized Gene Therapy Treatment market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Personalized Gene Therapy Treatment Market Report Provides Comprehensive Analysis of Following: ; Personalized Gene Therapy Treatment Market segments and sub-segments ; Industry size ; Personalized Gene Therapy Treatment shares ; Personalized Gene Therapy Treatment Market trends and dynamics ; Market Drivers and Personalized Gene Therapy Treatment Opportunities ; Supply and demand of world Personalized Gene Therapy Treatment industry ; Technological inventions in Personalized Gene Therapy Treatment trade ; Personalized Gene Therapy Treatment Marketing Channel Development Trend ; Global Personalized Gene Therapy Treatment Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Personalized Gene Therapy Treatment Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225585

Moreover, the report organizes to provide essential information on current and future Personalized Gene Therapy Treatment market movements, organizational needs and Personalized Gene Therapy Treatment industrial innovations. Additionally, the complete Personalized Gene Therapy Treatment report helps the new aspirants to inspect the forthcoming opportunities in the Personalized Gene Therapy Treatment industry. Investors will get a clear idea of the dominant Personalized Gene Therapy Treatment players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

Go here to read the rest:
Personalized Gene Therapy Treatment Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2029 3w Market News...

LONDON--(BUSINESS WIRE)--The global mycoplasma testing market size is expected to grow by USD 445.57 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of over 11%.

Request for Technavio's latest reports on directly and indirectly impacted marketsMarket estimates include pre- and post-COVID-19 impact on the mycoplasma testing market -

Download free sample report

The global outbreak of COVID-19 has compelled several companies in the healthcare industry to focus on finding a cure for this life-threatening disease. The number of pharmaceutical and biotechnology companies that focus on biomedical research is increasing, resulting in rising demand for mycoplasma testing to identify and eliminate mycoplasma contamination during the development of cell-derived biological and pharmaceutical products. However, the global outbreak of coronavirus is expected to have a neutral impact on the growth of the mycoplasma testing market during the forecast period.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

https://www.technavio.com/report/global-mycoplasma-testing-market-industry-analysis

The market is driven by the increasing focus on R&D of biopharmaceuticals. In addition, the growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies is anticipated to boost the growth of the mycoplasma testing market.

New class therapeutics such as cell therapy and gene therapy are gaining popularity as a novel treatment for many chronic and acute diseases. Thus, many pharmaceutical companies and research institutes are concentrating on the R&D of these products owing to their huge market potential. However, cell therapy products witness challenges around sterilization and its storage, as a result of which, it has to be immediately administered to the patients. Common mycoplasma species such as Acholeplasma laidlawii, Mycoplasma arginini, Mycoplasma bovis, Mycoplasma fermentans, and Mycoplasma salivarium have been identified as contamination in cell cultures and the biopharmaceutical processes. A product developed with mycoplasma contamination triggers serious side effects in humans. This is driving the demand for mycoplasma test kits. Rapid mycoplasma test kits are commercially available in the market that can be used in research labs and biopharmaceutical manufacturing companies for cell line qualification and in-process monitoring.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Mycoplasma Testing Companies:

Agilent Technologies Inc.

Agilent Technologies Inc. has business operations under various segments, such as life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The company's key offerings include MycoSensor PCR Assay Kit, 50 Rxn, which is a gel-based PCR assay that can rapidly detect mycoplasma infections in the human cell lines in less than four hours.

ATCC

ATCC operates its business through various segments, such as classic media, specialty media, stem cell research, human cytogenetics, mycoplasma detection, and molecular biology. The company's key products include Universal Mycoplasma Detection Kit, which offers a quick and sensitive PCR-based test to detect mycoplasma contaminants in cell culture.

Becton, Dickinson and Co.

Becton, Dickinson and Co. has business operations under various segments, such as BD Medical, BD Life Sciences, and BD Interventional. The company's key offerings include BD MAX System, which is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates its business through two segments: pharmaceuticals and diagnostics. The company's key offerings include MycoTOOL PCR Mycoplasma Detection Kit, which tests the absence of mycoplasma in cell culture samples. It supplies all reagents for the amplification step. It is an in-vitro amplification test optimized for detection of mycoplasma in cell culture.

InvivoGen

InvivoGen has business operations under various segments, such as research fields, biological tools, and custom services. The company offers PlasmoTest, which is the first assay to utilize cells to signal the presence of mycoplasma. It is a simple, rapid, and reliable assay for the visual detection of mycoplasma contamination in cell cultures.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Mycoplasma Testing Regional Outlook (Revenue, USD mn, 2020-2024)

Mycoplasma Testing End-user Outlook (Revenue, USD mn, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Link:
Analysis on Impact of COVID19-Global Mycoplasma Testing Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and ATCC | Technavio...

The recently published market study by GLOBAL MARKETERS.BIZ highlights the current trends that are expected to influence the dynamics of the Gene Therapy market in the upcoming years. The report introspect the supply chain, cost structure, and recent developments pertaining to the Gene Therapy market in the report and the impact of the COVID-19 on these facets of the market. Further, the micro and macro-economic factors that are likely to impact the growth of the Gene Therapy market are thoroughly studied in the presented market study.

Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#request_sample

Leading Players Are :

Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

Reasons to Trust Our Business Insights

Proven track record of delivering high-quality and insightful market studies

Data collected from credible sources including product managers, sales representatives, marketing executives, and more

Providing accurate insights for over ten industrial verticals

Swift delivery of reports with COVID-19 impact without any delays

Up-to-date market research and analytical tools used to curate market reports

Critical Data in the Gene Therapy Market Report

Company share analysis and competition landscape

Recent trends and notable developments in the Gene Therapy market space

Growth projections of each market segment and sub-segment during the forecast period

COVID-19 impact on the global Gene Therapy market

Recent innovations, product launches, and technological advances relevant to the Gene Therapy market

Regional Assessment

The regional assessment chapter in the report offers an out and out understanding of the potential growth of the Gene Therapy market across various geographies such as:

Application Assessment

The presented study ponders over the numerous applications of the Gene Therapy and offers a fair assessment of the supply-demand ratio of each application including:

Market Taxonomy

By Type

Ex vivoIn Vivo

By Application

CancerMonogenicInfectious diseaseCardiovascular diseaseOther

Enquire Here For Customization:

https://www.globalmarketers.biz/inquiry/customization/130925

By Region

North America

Latin America

Europe

China

Japan

SEA and Other APAC

MEA

Get Table of Contents with Charts, Figures & Tables https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#table_of_contents

The report resolves the following doubts related to the Gene Therapy market:

1. Who are the leading market players operating in the current Gene Therapy market landscape?

2. Which region is expected to dominate the Gene Therapy market in terms of market share and size during the forecast period?

3. What are the various factors that are likely to contribute to the growth of the Gene Therapy market in the upcoming years?

4. What is the most impactful marketing strategy adopted by players in the Gene Therapy market?

5. What is the projected CAGR growth of application 1 during the forecast period?

See more here:
Global Gene Therapy Market By Manufacturers, Types, Regions and Application and Forecast to 2025 - Cole of Duty

Sanofi chair Serge Weinberg on Thursday walked back entirely his CEO Paul Hudsons remarks that the US would have the right to the largest pre-order of the French drugmakers Covid-19 vaccine, should it be complete.

There will be no particular advance given to any country, Weinberg told France 2 television, according toReuters. The comments of our CEO have been altered. We consider vaccines as a common good.

Weinbergs comments joined a chorus among the board and the French government over the comments made Wednesday by Hudson, who insists he was misunderstood and had been calling only for Europe to take stronger action to support the development of a vaccine.

Remarking that a vaccine should be for the public good and that Hudsons comments affected French President Emmanuel Macron, a government official toldBloombergHudson and other Sanofi leadership were called to the presidential residence at the lyse Palace for a meeting. Earlier Thursday morning, when news of Macrons dissatisfaction first surfaced, Hudson said in an interview for the Financial Times Global Boardroom that it was news to him that the president wanted a meeting.

French Prime Minister douard Philippe also spoke out, saying on Twitter that a vaccine against Covid-19 should be a public good for the world.

After the company issued an initial statement walking back Hudsons comments on Wednesday saying that US production will be mainly for the US and ex-US production for Europe and the globe Weinberg and other members of Sanofis board spoke out out in greater force on Thursday.

Olivier Bogillot, chairman of Sanofis French unit, appeared on BFM Television and said there was no question about what would happen.

Obviously, if Sanofi makes a breakthrough on a vaccine for Covid-19 and it is effective, it will be made available to all, he said.

Hudson, appearing for a scheduled interview at the FT virtual conference, tried to clarify his remarks. The still relatively new CEO had toldBloombergthat the US would get the largest pre-order because the US bio-defense agency BARDA had financed their Covid-19 effort, backing it with a $30 million grant this year. He urged Europe to make a similar effort so countries on the continent dont get left behind.

What Im trying to say everywhere I go is that the US has BARDA, which is like a biological research group that gets ahead of these things earlier to get people ready and to try to make sure the necessary capacity is built and the risks are shared, he said. My comments are really around what do we need to do to make sure were in a similar position in Europe. It was never a choice. We need to get vaccines to everybody.

Experts warn, though, that when Covid-19 vaccines do arrive, they will come in batches, forcing potentially difficult decisions about who gets the first doses. AstraZeneca CEO Pascal Soriot said last month that the UK would get early access to the vaccine they are producing with Oxford University.

Ousted BARDA chief Rick Bright said at a whistleblower hearing Thursday that the US has a placeholder to order doses from some of the vaccine companies it funded. The agency has put around $1 billion to back J&J and Modernas efforts. In addition to the $30 million this spring, the agency has given Sanofi and its recombinant vaccine subsidiary Protein Sciences hundreds of millions in grants over the last 15 years.

The United States has a placeholder with some of those companies to be able to place orders for those vaccines when they are available, Bright said. And we did everything possible to ensure that those investments were in companies that would build capacity in the United States to manufacture those vaccines. We had to get in line first.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

Read the original here:
Serge Weinberg issues sharp reversal as board, French government react to CEO Paul Hudson's vaccine remarks - Endpoints News

ReportsnReports recently added a detailed overview and industry professional survey report on the global Longevity and Anti-senescence Therapy Market. In this report, titled Longevity and Anti-senescence Therapy Market Size, Share and Industry Analysis by Technologies, By Product, By Application, By Distribution Channel, and Regional Forecast 2019-2026.

Download a Sample Copy of Report athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2255402

The scope of the report encompasses the major types of Longevity and Anti-senescence Therapy Market that have been used, as well as the major applications being developed by industry, academic researchers and their commercialization offices, and government agencies. It analyzes the current market status, examines future market drivers, and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed. Other influential factors such as screening strategies for pharmaceuticals have also been included.

The global Longevity and Anti-senescence Therapy Market is comprehensively profiled in the report, including a detailed study of the markets key drivers and restraints, major market players, and leading segments.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Any Query or Discount? Ask our Expert athttps://www.reportsnreports.com/contacts/discount.aspx?name=2255402

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary:

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. ?Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for ?life expectancy in the demography. ?Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

Click Here & Get a Single User OR Corporate User License Key for This Report athttps://www.reportsnreports.com/purchase.aspx?name=2255402

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

The latest Longevity and Anti-senescence Therapy Market report provides readers with a deeper understanding of potential target consumers to create a lucrative marketing strategy for the 2019-2026 forecast period. For entrepreneurs seeking information about potential customers, it will be particularly helpful. Selective statements provided by leading vendors would allow entrepreneurs to gain a deeper understanding of the local market and prospective customers.

Table of Contents:

Chapter 1 Introduction

Study Background

Study Goals and Objectives

Reasons for Doing This Study

Scope of Report

Methodology and Information Sources

Geographic Breakdown

Market Breakdown

Analysts Credentials

.Continued

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.We provide 24/7 online and offline support to our customers.

E-mail: [emailprotected]

Phone: +1 888 391 5441

Follow this link:
Longevity and Anti-senescence Therapy Market Projected to Experience Major Revenue Boost During the Forecast Period Between 2020-2026 | Covid-19...

Latest Market Research Report onBispecific Antibody Therapeutic Market size | Industry Segment by Applications (Osteology, Pulmonary, Respiratory Diseases, Oncology and Gene Therapy), by Type (Bearing An Fc Region and Lacking An Fc Region), Regional Outlook, Market Demand, Latest Trends, Bispecific Antibody Therapeutic Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The recent report on Bispecific Antibody Therapeutic market provides a comprehensive analysis of this industry scenario with respect to an array of pivotal parameters. As per the study, the market will accumulate momentous gains by the end of the analysis period and will register a decent growth rate during the forecast timeline.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/10005

The report encompasses significant details about the various segments of the Bispecific Antibody Therapeutic market. It offers information pertaining to global revenue forecast, regional & country-wise market shares, sales patterns, along with other actionable insights. In addition, it examines the competitive landscape to estimate the impact of global & domestic market players, while listing the parameters and opportunities defining the business outlook.

Report Scope:

Bispecific Antibody Therapeutic market competition by top Manufacturers:

Bispecific Antibody Therapeutic Market Outlook by Applications:

Bispecific Antibody Therapeutic Market Statistics by Types:

The report highlights Bispecific Antibody Therapeutic market with reference to the regional landscape:

Other insights outlined in the Bispecific Antibody Therapeutic market report is listed below:

The study presents information related to the growth margins of the firms as well as the manufacturing expenses, renumeration and product costs.The Bispecific Antibody Therapeutic market research report involves data that speaks about the level to which the industry has been evaluated. Information regarding the analysis of new projects undertaken as well as the conclusions have been inculcated in the report.

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/10005

Read the original here:
Bispecific Antibody Therapeutic Market Share Analysis and Research Report by 2025 - ZZReport